Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.

cls.cnNov 13, 2024 08:52 ET

Investors further inquired about the progress of the GLP-1 new drug review. Hebei Changshan Biochemical Pharmaceutical responded that the registration inspection has been completed and the approval time cannot be estimated. Directly focus on the earnings

①At today's earnings conference, investors repeatedly inquired about the progress and approval time of the GLP-1 drug Aibonapeptide injection, with management stating that it is unpredictable; ②Management revealed that the on-site verification and registration inspection of Aibonapeptide have been completed, and clinical trials for weight loss indications have not yet been initiated; ③Regarding the decline in performance compared to multiple quarters, management stated that they will speed up going global to restore the profitability of the heparin business.

cls.cnOct 15, 2024 06:13 ET

Cisen Pharmaceutical's sales volume of the winning varieties in the centralized procurement has increased significantly. It is predicted that the sales of the large infusion sector will trend towards stability in the second half of the year. | Live from t

①At the earnings conference, the director of Cisen Pharmaceutical, Xu Xinbing, explained the gross margin and revenue decline of the company in the first half of the year. ②Xu Xinbing said that the company's sales volume of four varieties that were awarded in the eighth batch of centralized procurement showed a significant year-on-year increase. ③Du Zhenxin, the chairman of the company, introduced the company's development of generic drugs and innovative drugs.

cls.cnSep 9, 2024 05:55 ET

The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.

Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.

cls.cnAug 28, 2024 19:29 ET

Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25, 2024 03:26 ET

Robinhood CEO Says Exchange Is Ready For Roaring Kitty Livestream Surge: 'We Are Prepared' For GameStop Frenzy

BenzingaJun 6, 2024 18:20 ET